Mechanistic Target of Rapamycin Complex 1
"Mechanistic Target of Rapamycin Complex 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An evolutionarily conserved multiprotein complex that functions as a cellular energy sensor and regulator of protein synthesis for cell growth and proliferation. It consists of TOR SERINE-THREONINE KINASES; REGULATORY-ASSOCIATED PROTEIN OF MTOR (RAPTOR); MLST8 PROTEIN; and AKT1 substrate 1 protein. The activity of the complex is regulated by SIROLIMUS; INSULIN; GROWTH FACTORS; PHOSPHATIDIC ACIDS; some amino acids or amino acid derivatives, and OXIDATIVE STRESS.
| Descriptor ID |
D000076222
|
| MeSH Number(s) |
D05.500.337 D08.811.913.696.620.682.700.931.500 D12.776.476.925.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mechanistic Target of Rapamycin Complex 1".
Below are MeSH descriptors whose meaning is more specific than "Mechanistic Target of Rapamycin Complex 1".
This graph shows the total number of publications written about "Mechanistic Target of Rapamycin Complex 1" by people in this website by year, and whether "Mechanistic Target of Rapamycin Complex 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 3 | 3 |
| 2016 | 1 | 6 | 7 |
| 2017 | 1 | 2 | 3 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 2 | 2 |
| 2026 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mechanistic Target of Rapamycin Complex 1" by people in Profiles.
-
Association of genomic driver mutation, histologic subtype, and mTORC1 biomarker expression in mTOR pathway-altered renal tumors. Hum Pathol. 2026 Sep; 175:106154.
-
Tissue and CD4 T cell subset dependence on the amino acid transporter SLC38A1. Cell Metab. 2026 Apr 07; 38(4):712-728.e6.
-
Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. Cell Chem Biol. 2026 Jan 15; 33(1):59-73.e10.
-
Creatine kinase B regulates glycolysis and de novo lipogenesis pathways to control lipid accumulation during adipogenesis. Cell Rep. 2025 11 25; 44(11):116489.
-
Conformation-specific synthetic intrabodies modulate mTOR signaling with subcellular spatial resolution. Proc Natl Acad Sci U S A. 2025 Jun 17; 122(24):e2424679122.
-
Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. Nature. 2024 06; 630(8018):968-975.
-
Iron drives anabolic metabolism through active histone demethylation and mTORC1. Nat Cell Biol. 2023 10; 25(10):1478-1494.
-
mTORC1-independent translation control in mammalian cells by methionine adenosyltransferase 2A and S-adenosylmethionine. J Biol Chem. 2022 07; 298(7):102084.
-
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2022 02; 6:e2100448.
-
MTHFD2 is a metabolic checkpoint controlling effector and regulatory TÂ cell fate and function. Immunity. 2022 01 11; 55(1):65-81.e9.